性取向与针对猴痘的天花疫苗接种意愿相关:日本一项横断面初步调查
2022年9月至10月在日本开展横断面在线调查,纳入指定男性12,900人和指定女性13,413人。同性恋受访者接种意愿高于异性恋者,指定男性中比例为23.1%、指定女性中为13.4%;校正后同性恋取向与接种意愿显著相关,患病率比分别为1.37(95%CI:1.23-1.54)和1.34(95%CI:1.13-1.59)。
要点
- 同性恋受访者针对猴痘的天花疫苗接种意愿高于异性恋者。
- 指定男性中同性恋者接种意愿比例为23.1%,指定女性中为13.4%。
- 校正后患病率比:指定男性1.37(95%CI:1.23-1.54),指定女性1.34(95%CI:1.13-1.59)。
核心结论
- 同性恋取向与针对猴痘的天花疫苗接种意愿显著相关,指定男性患病率比1.37(95%CI:1.23-1.54),指定女性1.34(95%CI:1.13-1.59)。
研究设计与样本
- 2022年9月至10月在日本开展的横断面在线调查,指定男性12,900人、指定女性13,413人参与。
- 采用改良泊松回归分析接种意愿与性取向的关系,校正社会经济因素、对政府的信任、COVID-19疫苗接种状态和性交易场所访问频率。
主要发现
- 同性恋受访者接种意愿高于异性恋者,指定男性中比例为23.1%,指定女性中为13.4%。
- 同性恋取向与接种意愿显著相关,指定男性患病率比1.37(95%CI:1.23-1.54),指定女性1.34(95%CI:1.13-1.59)。
临床怎么用
- 作者认为这些发现凸显了针对高风险群体开展针对性疫苗推广活动和持续监测猴痘相关态度及疫苗依从性的必要性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This survey aimed to assess the prevalence of intention to receive smallpox vaccine against mpox and its relationship with sexual orientation in Japan. A cross-sectional online survey was conducted in September-October 2022, with 12,900 assigned males and 13,413 assigned females participating. Modified Poisson regression analyses were performed to determine the relationship between vaccine willingness and sexual orientation, adjusting for socioeconomics, trust in government, COVID-19 vaccination status, and frequency of brothel visits. Vaccine willingness was higher in homosexual respondents than heterosexual counterparts, with proportions of 23.1 % among assigned males and 13.4 % among assigned females. Homosexual orientation was significantly associated with vaccine willingness, with prevalence ratios of 1.37 (95 % CI: 1.23-1.54) among assigned males and 1.34 (95 % CI: 1.13-1.59) among assigned females. These findings highlight the need for targeted vaccine promotion campaigns and ongoing monitoring of attitudes towards mpox and vaccine compliance in high-risk groups.
引用
- Hori D, Kaneda Y, Ozaki A, et al. Sexual orientation was associated with intention to be vaccinated with a smallpox vaccine against mpox: A cross-sectional preliminary survey in Japan. Vaccine. 2023. PMID: 37236819. doi:10.1016/j.vaccine.2023.05.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。